

## Synthesis, Characterization and Preliminary Anti-Microbial Evaluation of New Flurbiprofen Hydrazide Derivatives

Hawraa Yusur Jassim<sup>\*1</sup> and Mohammed Kamil Hadi<sup>2</sup>

<sup>1</sup>Iraqi Ministry of Health, Department of Health in Baghdad, Russafa, Baghdad, Iraq

<sup>2</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.

\*Corresponding author

Received 20/1/2024, Accepted 26/5/2024, Published 15/2/2025



This work is licensed under a Creative Commons Attribution 4.0 International License.

### Abstract

A new series of 2-(2-fluoro-[1,1'-biphenyl]-4-yl) propanoic acid derivatives were synthesized to enhance their Anti-Microbial activities. The new flurbiprofen hydrazone compounds (**4a-e**) prepared by reacting flurbiprofen ethyl ester with hydrazine hydrate to yield flurbiprofen hydrazid(**3**). Then compound (**3**) reacted with several aromatic aldehydes in absolute ethanol in presence of a small amount of glacial acetic acid to yield final compounds (4a-e). FT-IR and <sup>1</sup>H-NMR spectroscopy were utilized for the characterization of the final compounds. Molecular docking showed that there were significant molecular docking results with target protein for compounds 4d and 4a when compared to ciprofloxacin as reference. The ADMET study was conducted in order to predict the pharmacokinetic properties of the final compounds. The final compounds have acceptable estimated drug-like properties as well as desirable pharmacokinetics properties. Each final compound was examined for its Anti-Microbial efficiency against G(+)-ve bacteria (*Streptococcus pyogenes*, *Staphylococcus aureus*), G(-)-ve bacteria (*Escherichia coli*, *Klebsiella pneumoniae*) and strain of fungi (*Candida albicans*). Compound (**4e**) exhibited the highest Anti-Microbial efficiency against both strains G(-)-ve and G(+)-ve bacteria. Additionally, compound (**4b**) exhibits a good action for both strains. All synthesized compounds exhibit high antifungal activity except compound (**4b**) against *candida albicans* when compared to the standard compound, fluconazole.


**Keywords:** Flurbiprofen, Hydrazine Hydrate, Anti-Microbial Activity, Aromatic aldehyde, NSAID.

### Introduction

One of the causes of death and morbidity nowadays is antimicrobial drug resistance, which has led scientists to focus on the rise in multidrug-resistant microorganisms as a significant issue in recent years<sup>(1)</sup>. Many investigations demonstrate that non-steroidal anti-inflammatory drugs (NSAIDs) have antibacterial action against a variety of Gram-positive and Gram-negative pathogens, which reduces bacterial adhesion and biofilm formation<sup>(2, 3)</sup>. One NSAIDs with anti-inflammatory, antipyretic, and analgesic properties is flurbiprofen, which is widely used to treat rheumatoid arthritis, osteoarthritis, migraines, acute gout, pain, and inflammation<sup>(4-8)</sup>. The review of the literature showed that the aryl carboxylic acid modification of NSAIDs produces anti-inflammatory, anti-bacterial, fungi toxicity, antiviral, and in vitro cytotoxic effects<sup>(9-11)</sup>.

Many studies reveal that hydrazones are known to inhibit a variety of bacterial species<sup>(12)</sup> and also show antitumoral, antimalarial, antiviral, and antitubercular activities<sup>(13-16)</sup>.

Hydrazones can be created by the displacement of oxygen from ketone or aldehyde with the R<sub>1</sub>R<sub>2</sub>C=NNH<sub>2</sub> moiety by reacting with hydrazide<sup>(17, 18)</sup>.



**Figure1. Chemical structure of flurbiprofen**

### Materials and Methods

#### ADMET studies

In order to assess drug likeness properties, all final compounds are subjected to ADMET prediction using Qikprobe software in Schrodinger maestro **Docking study**

Using the Glide application integrated with the maestro software from licensed Schrodinger. The crystal structure of the *Staphylococcus aureus* gyrase enzyme in combination with DNA and ciprofloxacin was made available by the Protein Data Bank (PDB ID: 2XCT)<sup>(19)</sup>. Eliminate all water molecules and add hydrogen atoms to the amino acid residues to bring them to the correct tautomeric state and ionization<sup>(20)</sup>. The cocrystallized ligand that interacted with the

protein was used to create the receptor grid. The collection of ligands to be docked was identified and prepared using ligprep. The prepared ligands were docked to the gyrase enzyme (PDB ID: 2XCT) using the default XP docking option, which limited out to 10 poses<sup>(21)</sup>. The co-crystallized ligand was re-docked into the binding site using the same set of parameters as previously mentioned in order to validate the docking research at the 2XCT-active site<sup>(22)</sup>.

### Chemicals


Flurbiprofen and 4-hydroxy-2-nitrobenzaldehyde are obtained from Picasso-e Company, ethanol from Honeywell Company, hydrazine hydrate from Thomas Baker Company, and all other compounds from Sigma-Aldrich Company, including 3-thiophencarboxyaldehyd, Syringaldehyde, pyrrole-3-carboxaldehyde. The melting points were uncorrected and measured using the Stuart SMP30 apparatus. Reaction completion and the products' purity were examined by Thin-Layer Chromatography (TLC) method with an Aluminum-Precoated silica sheet material (Germany, Merck). Each target compound dot was observed by a UV 254 nm lamp. The infrared spectra were obtained at Bagdad University, Pharmacy

College using ATR–FTIR (Shimadzu, Japan) device with the unit of measurement symbol ( $\nu, \text{cm}^{-1}$ ). <sup>1</sup>H-NMR was done using a Bruker model 400 MHz at Basra, Iraq, and DMSO was used as a solvent. The synthesized target compounds were tested for antibacterial properties, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) at the office located in Baghdad, Iraq named chemistry analysis center (CAC).

### Chemical synthesis

#### Synthesis of flurbiprofen ester[ethyl 2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoate] Compound 2<sup>(23,24)</sup>:

After dissolving flurbiprofen (5g, 0.02mol) in absolute ethanol, 15 drops of H<sub>2</sub>SO<sub>4</sub> were added, mixed, and refluxed at 78 °C for 6 hours (hrs). Reaction completion is checked by utilizing TLC. The solution then was neutralized by 10% NaHCO<sub>3</sub>. Diethyl ether was used to separate the oily crude product. To get compound 1, the organic layer was evaporated. Yellowish oil was obtained. Yield: 88%, R<sub>f</sub> = 0.8 (ethanol: n-hexane 4:6), Infra R<sub>ed</sub> ( $\nu \text{ cm}^{-1}$ ): 1732.08:(carbonyl) strch. Ester func. group, 1180:(C-O bond) strch. ether.




Scheme 1. Synthetic mechanism of flurbiprofen ethyl ester compound 2<sup>(25)</sup>

#### Synthesis of flurbiprofen hydrazide [2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide] Compound 3<sup>(26,27)</sup>

Hydrazine hydrate 99% (5mL, 0.11 mole) mixed with solution of compound 2 (2g, 0.007 mole) in 30 mL of absolute ethanol, then the combination refluxed at 78 °C for twenty hours. The solution was

then cooled at (25°C) temperature, then decanted over ice with continuous mixing. The solid after that filtered and recrystallized by ethanol. Yield: 85%, MP (114-116°C), R<sub>f</sub> = 0.3 (ethanol :n-hexane 4:6), Infra-Red{IR} ( $\nu \text{ cm}^{-1}$ ): 1631 (Carbonyl) strch. of amide functionality, 3309.85, 3286.7 ((N-H)) strch. of NH<sub>2</sub>, 3032.10: (C-H bond) strch. of Ar. C-H.




Scheme 2. Synthetic mechanism of flurbiprofen hydrazide compound 3<sup>(28)</sup>

**Synthesis of Hydrazone [2-(2-fluoro-[1, 1'-biphenyl]-4-yl)propanehydrazide] derivatives. Compounds 4(a-e)** <sup>(29,30)</sup>

Several aromatic aldehydes (a-e) (0.005 moles) were mixed with Compound 3 (0.005 moles, 0.8 gm) in 30 mL of absolute ethanol and 4 drops of glacial

acetic acid. At 76°C, the solution then was refluxed for 20 hours then left till to cool at (25°C) temperature, filtered and ethanol was used to re-crystallize the solid compound.



Scheme 3. Synthetic mechanism of

hydrazone compounds (Iva-e)<sup>(31)</sup> 2-(2-fluoro-[1,1'-biphenyl]-4-yl)-N'-(thiophen-3-ylmethylene)propanehydrazide (4a) gray powder, Yield =96%, MP=159-161 °C,  $R_f$ =0.94 (ethanol, n-hexane 4:6), IR ( $\nu$  cm<sup>-1</sup>):3194.12(N-H) str. of secondary amide,3097,3020: (C-H) str. of Ar- ring ,2985: (C-H) asymm. str. of CH<sub>3</sub> CH, 2850:(C-H)

Symm.str. of CH<sub>3</sub>, CH, 1651:(C=O) str. Of amide,1604: (C=N) str. of imin,1512:(N-H) bending vibration, 694:(C-S) str. <sup>1</sup>HNMR: 1.44(3H,d- CH<sub>3</sub> , 3.76-4.75 (1H, qq - CH),7.28-8.01(11 H, m -Ar-H),8.02- 8.29 (1H, ss- N=CH),11.34-11.54(1H , ss-NH).

**2-(2-fluoro-[1,1'-biphenyl]-4-yl)-N'-(4-hydroxy-2-nitrobenzylidene)propanehydrazide(4b)** yellow powder, Yield = 94% MP= (176-178°C),  $R_f$  = 0.76 (ethanol, n-hexane 4:6), IR (v  $\text{cm}^{-1}$ ):3267.41:(O-H) str. of OH, 3194.12 :(N-H) str. of secondary amide,3036.96: (C-H) str. of Ar-H, 2984:(C-H) Asymmtr. strch. of CH<sub>3</sub>,CH, 2904:((C-H)) Symmtr. str. Of aliph. CH<sub>3</sub>,CH ,1654.92(C=O) strch. of amide fun. Gp., 1624.06:(C=N) strch. of imin, 1535,1319.31(nitro) of NO<sub>2</sub>. <sup>1</sup>HNMR,1.43(3H , d – CH<sub>3</sub>), 3.75-4.73 (1H , qq – CH),7.18- 7.91(11H , m- Ar\_H), 8.17 (1H , s- N=CH), 11.08(1H , s – OH),11.44-11.68(1H ,ss-NH).

**2-(2-fluoro-[1,1'-biphenyl]-4-yl)-N'-(4-hydroxy-3,5-dimethoxybenzylidene)propanehydrazide(4c)** White powder, Yield =70% MP= (201-203°C),  $R_f$ =0.64 (ethanol, n-hexane4:6), (IR) (v $\text{cm}^{-1}$ ):3545:(hydroxyl) strch. of OH group, 3186.4 :(N-H) strch. of 2° amide func. group, 3056: (C-H) strch. of Aromatic C-H, 2978:(C-H) asymm.strch. of CH, CH<sub>3</sub>,2846.93: (C-H) symm.strch. of CH, CH<sub>3</sub>, 1662.64 (C=O) strch. of amide func. group, 1643.35:(C=N) strch. of imin func. group,1581.63:(N-H) bending vibration band, <sup>1</sup>HNMR, 1.44(3H, d, CH<sub>3</sub>), 3.83(6H, s, CH<sub>3</sub>), 4.71(1H, q-CH) , 6.93-7.79(10H , m- Ar\_H) ,8.09-8.87(1H , ss.- N=CH),8.93(1H , s-OH),11.31-11.48(1H , ss-NH).

**N'-((1H-pyrrol-3-yl)methylene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide(4d)** brown powder, Yield =80% MP= (181-182°C), $R_f$ =0.44 (ethanol, n-hexane 3:7), IR spectroscopy (v  $\text{cm}^{-1}$ ): 3267.41: (N-H) strch. of pyrrole,3194:(N-H) strch. of 2° amide gp.,3051:(C-H) strch. of Ar. C-H,2981:(C-H) asymm.strch. of aliphatic CH, CH<sub>3</sub>,2854.65:(C-H) symm.strch. of CH,CH<sub>3</sub>, 1651:(C=O) strch. of amide functionality,1608 (C=N bond) strch. of imin group, <sup>1</sup>HNMR, 1.43(3H , d-CH<sub>3</sub>) ,3.73-4.90(1H , qq-CH) , 6.11-7.8(11H , m.-Aroma. \_H) ,7.8-8.05 (1H ,ss- N=CH) ,11.09-11.29 (1H , ss-ArNH), 11.41-11.47(1H , ss-NHC=O).

**N'-(4-chlorobenzylidene)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanehydrazide(4e)**white powder Yield = 94% MP = (176-177°C),  $R_f$  = 0.9 (ethanol, n-hexane 2:8) , IR spectro.(v  $\text{cm}^{-1}$ ):3178 :(N-H) strch. of 2° amide grp., 3059.10 (C-H) strch. of Ar. C-H bond, 2974:((C-H))asymmtr. Strch. Of alphtc. CH<sub>3</sub>,CH, 2877:(C-H) symm. Srech. Of CH<sub>3</sub>,CH, 1662(C=O) strch. of amide, 1612(C=N) strch. of imin, 763,694:(C-Cl)str. <sup>1</sup>HNMR,1.44 (3H, d, CH<sub>3</sub>),

3.81-4.75(1H , qq, CH),6.88-7.97(12H , m- Ar\_H),8.26(1H , s- N=CH), 11.46-11.81(1H , ss-NH).

#### Antimicrobial Activity <sup>(32)</sup>

Each ultimate compound (4a-e) was evaluated for its Anti-Microbial property against number of bacteria{ two G(-)ve bacteria (*E. coli* ,*Klebsiella pneumonia*), two G(+ve) bacteria (*Streptococcus aureus* and *Staphylococcus aureus*)}, and one fungus (*Candida albicans*) utilizing the disc diffusion technique. All the final compounds had a 1000 $\mu\text{g}/\text{ML}$  concentration, using DMSO as a solvent. The activity was then confirmed through measurement the inhibition zone in unit millimeters(ml) and comparing it to the antibacterial agents (amoxicillin, ciprofloxacin) and antifungal one (fluconazole) as reference.

## Results and Discussion

### Docking study

Compounds (4a-e) were subjected to molecular docking to explore their possible interactions within the active site of gyrase enzyme (PDB: 2XCT). Protein residues, the Mn<sup>+2</sup> ion, and DNA bases make up the binding pocket for the reference medication, ciprofloxacin. The binding process between the ligand and protein requires Mn<sup>+2</sup> ion interaction with the ligand. In this work compounds 4d and 4a have higher docking score than that of ciprofloxacin that is -8.430 for compound 4d , -8.197 for compound 4a and -8.164 for ciprofloxacin. As illustrated in Figure (2) Compound 4d has hydrogen bond interaction between NH of pyrrole ring and amino acid residue GLU1088 also there was metal coordination interactions between pyrrole ring and Mn2000 . Another hydrogen bond interaction occurred between NH of amide group and DNA nucleotide DG8. pi-pi stacking interactions between aromatic ring of compound 4d and DNA nucleotides DG8 and DG9 . Compound 4a has metal coordination interactions between thiophene ring and Mn2000 , hydrogen bond interaction between NH of amide group and DNA nucleotide DG8, hydrogen bond interaction between C=O group amino acid residue SER1084, pi-pi stacking interactions between aromatic ring of compound 4a and DNA nucleotides DG8 ,DG9 and DC13 . In contrast ciprofloxacin has pi-pi stacking interactions between its aromatic rings and DNA nucleotides DG8 and DG9 as well as metal coordination interactions between Mn<sup>2+</sup> and two C=O groups.




Figure 2. Two-Dimensional docking pose of A:4d, B:4a and C: ciprofloxacin into the gyrase active site (PDB:2XCT)

### ADMET Studies

As illustrated in Table(1), all final compounds had appropriate expected pharmacokinetic parameters such as Percent oral absorption, rule of five, rule of three, and metabolism. Since compound 4b and 4c don't activate CNS, they have no CNS side effects.

All synthesized compounds (4a-e) have between one and four metabolic reactions. Every synthesized compound has a high proportion of oral absorption. All synthesized compounds (4a-e) have only one rule of three violation, while compounds 4b and 4d do not violate the rule of five.

**Table1. The predicted ADMET data for the final compounds(4a-e)**


Compound	CNS	#metab	Percent Human Oral Absorption	Rule Of Five	Rule Of Three
4a	0	2	100	1	1
4b	-2	3	93	0	1
4c	-2	4	100	1	1
4d	0	1	100	0	1
4e	0	1	100	1	1

CNS; suggested a scale for central nervous system activity ranging from -2 (inactive) to +2 (active). #metab; Probable number of metabolic reactions: 1-8. **Percent Human Oral Absorption**; >80% is high, <25% is poor. **Rule Of Five**; There are a maximum of four instances of breaking Lipinski's rule of five. **Rule Of Three**; There are a maximum of three violations of Jorgensen's rule of three<sup>(33)</sup>.

### Chemistry

Scheme 4 showed the overall synthetic process leading to the final compounds (4a-e). It begins with flurbiprofen ethyl ester (2), which is produced by reacting ethanol with flurbiprofen that has been dissolved in ethanol in the presence of H<sub>2</sub>SO<sub>4</sub>. Compound 2's ATR-FTIR spectra revealed an absorption band at (1732.08 cm<sup>-1</sup>) owing to the ester carbonyl's C=O and (1180 cm<sup>-1</sup>) due to the ether's C-O stretching vibration. Compound 2 was refluxed with 99% hydrazine hydrate in absolute ethanol to produce flurbiprofen hydrazide. Compound 3's ATR-FTIR spectroscopy analysis revealed an absorption band at (1631.78 cm<sup>-1</sup>) for the amide's carbonyl stretching vibration, and (3309.85, 3286.7 cm<sup>-1</sup>) for the primary amine's stretching vibration. Compound 3 was refluxed with various aromatic aldehydes (3-thiophenecarboxyaldehyd, 4-hydroxy-

2-nitrobenzaldehyde, Syringaldehyde, pyrrole-3-carboxaldehyde, 4-Chlorobenzaldehyde) in absolute ethanol with the presence of glacial acetic acid to create compound (4a-e). ATR-FTIR of compounds (4a-e) spectra reveal an absorption band of the amide's C=O str. at (1662-1651 cm<sup>-1</sup>) and the imin's C=N str. vibration at (1643-1604 cm<sup>-1</sup>) and disappearance of amine's band. <sup>1</sup>HNMR spectroscopy revealed a signal at (11.68-11.31) representing the NH proton and a singlet signal at (8.06-8.29) representing the proton of the imin group. The presence of C=N group explains the existence of E and Z geometrical isomers and appearance of two signals for N=CH and CO-NH. Hydrazone generally occurs as cis/trans amide conformers and as an E or Z isomer around the C=N double bond<sup>(34,35)</sup>.



**Scheme4. Chemical synthesis of final compounds (4a-e)**

**Anti-microbial activity**


Using amoxicillin, ciprofloxacin and fluconazole as positive controls, the Anti-Microbial activity of the synthesized derivatives (4a–e) was assessed using the disc well diffusion method on G(+ve), G(-)ve bacteria and fungi. As indicated in the following Table (2), DMSO was employed as both a solvent and a negative control. Compound

(4e) revealed maximal Antibacterial property for both strains of bacteria{ G(+ve) and G(-)ve Figure(3). The (4b) compound also exhibited good Antibacterial property for both bacterial strains. All synthesized compounds except compound (4b) exhibited high antifungal activity compared with fluconazole.

**Table2. The zone of inhibition of final compounds (4a-e)**

Compound	Inhibition zone (mm)					
	Conc. µg/ml	S. aureus	S. pyogenes	K. Pneumonia	E.Coli	C.albicans
4a	10 <sup>3</sup>	18	17	18	22	22
4b	10 <sup>3</sup>	20	22	18	25	8
4c	10 <sup>3</sup>	18	16	20	25	20
4d	10 <sup>3</sup>	14	15	15	24	22
4e	10 <sup>3</sup>	22	25	18	25	20
Amoxicillin	10 <sup>3</sup>	24	25	22	20	-
Ciprofloxacin	10 <sup>3</sup>	25	25	25	30	-
Fluconazole	10 <sup>3</sup>					20
DMSO		Control and solvent				

No activity= (-), slightly active=(zone of inhibition between 5–10 mm, moderately active=(zone of inhibition between 10-15mm), highly active =(zone of inhibition more than 15 mm)



**Figure 3 .Zone of inhibition(mm) of compounds (4a-e)**

**Statistical analysis**

Two-factor without replication ANOVA TEST was used for antibacterial activity( Table3, Figure4) and one-way ANOVA TEST was used for antifungal activity (Table4, Figure5) . The α value is equal to 0.05, and the values are shown as the mean ± SEM of triplicate measurements of the zone of inhibition.

**Table3. Antibacterial statistical analysis of final compounds (4a-e)**

Compounds	Mean ± SEM			
	S. aureus	S. pyogene	K. pneumonia	E. coli
4a	17.667±0.459*#	16.667±0.459*#	17.667±0.459*#	21.333±0.459#
4b	21.000±0.459*#	22.333±0.459*#	17.000±0.459*#	24.667±0.459*#
4c	17.667±0.459*#	16.333±0.459*#	20.333±0.459*#	24.333±0.459*#
4d	14.333±0.459*#	14.667±0.459*#	14.667±0.459*#	22.333±0.459*#
4e	22.333±0.459#	24.667±0.459	17.667±0.459*#	24.667±0.459*#

\*Significant difference with respect to Amoxicillin P<0.05). #Significant difference with respect to Ciprofloxacin P<0.05)




Figure4. Histogram of the antibacterial inhibition zone of tested compounds (4a-e)

Table4. Antifungal statistical analysis of final compounds (4a-e)

Mean ± SEM	
Compounds	<i>C. albicans</i>
4a	21±0.544
4b	7.333±0.544*
4c	19.666±0.544
4d	21.666±0.544*
4e	20.333±0.544

\*Significant difference with respect to Fluconazole P<0.05).




Figure5. Histogram of the antifungal inhibition zone of tested compounds(4a-e)

**Minimum bactericidal concentration (MBC)**

Compound (4a) was more effective than amoxicillin against both G(+ve and G(-)ve bacteria, although it had less bactericidal activity than

ciprofloxacin and same MBC in comparison to fluconazole. Although compound( 4d) also had good MBC, it was less effective than compound( 4a) (Table5).



**Table5. Minimum bactericidal concentration of final compounds (4a-e)**

Compound	Minimum bactericidal concentration µg/ml				
	<i>S. aureus</i>	<i>S. pyogenes</i>	<i>K. Pneumonia</i>	<i>E.Coli</i>	<i>C.albicans</i>
4a	250	500	1000	500	250
4b	500	1000	500	500	500
4c	500	1000	1000	1000	500
4d	250	500	500	1000	500
4e	500	1000	1000	1000	1000
Amoxicillin	500	500	500	1000	-
Ciprofloxacin	250	250	250	500	-
Fluconazole					250

**The minimum inhibitory concentration (MIC)**

All compounds are less effective than ciprofloxacin and have the same potency as amoxicillin against gram negative bacteria, however compounds 4a and 4d are more potent than

amoxicillin and have the same potency of ciprofloxacin against gram positive bacteria. Compound 4a is the only one that has the same antifungal potency as fluconazole (Table6, Figure6).

**Table6. The minimum and sub-minimum inhibitory concentration of the final compounds (4a-e)**

Isolates	4a		4b		4c		4d		4e		AMOX.		CIP.		FLC.		
	MIC	SUB	MIC	SUB	MIC	SUB	MIC	SUB	MIC	SUB	MIC	SUB	MIC	SUB	MIC	SUB	
<i>S. aureus</i>	125	62.5	250	125	250	125	125	62.5	250	125	250	125	62.5	125	62.5	125	62.5
<i>S. pyogen</i>	250	125	500	250	500	250	250	125	500	250	250	125	125	62.5	125	62.5	
<i>K. Pneumonia</i>	250	125	250	125	1000	500	500	250	500	250	500	250	250	125	125	250	125
<i>E. coli</i>	500	250	250	125	500	250	250	125	500	250	250	125	125	125	62.5	125	62.5
<i>C.albicans</i>	125	62.5	250	125	250	125	250	125	250	125	250	125	125	62.5	125	62.5	

AMOX: amoxicillin, CIP: ciprofloxacin, FLC: fluconazole



**Figure6. The minimum inhibitory concentration of final compounds (4a-e)**

**Conclusion**

New flurbiprofen derivatives synthesized and examined for Anti-Microbial activity by using the

disc diffusion method. Among which compound( 4e) exhibited the highest Anti - Microbial activity

and Compound (4 b) also showed a good antibacterial activity which is may be due to the presence of electron withdrawing groups (CL) for (4e) and (NO<sub>2</sub>) for (4b) compound. Also presence of OH group and formation of H bond may influence antibacterial activity of compound (4 b). Whole synthesized compounds except compound (4b) exhibited a high antifungal activity. The virtual ADMET studies revealed that the final compounds(4a-e) had acceptable pharmacokinetic characteristics. Compound 4d and 4a had higher docking score than ciprofloxacin, according to a docking study. Each ultimate compound was distinguished by ATR-FTIR and <sup>1</sup>HNMR.

### Acknowledgement

The authors are grateful to the department of pharmaceutical chemistry in the college of pharmacy, University of Baghdad for providing the research facilities.

### Conflicts of Interest

There is no conflict of interest regarding the publication of this manuscript.

### Funding

The authors received no financial support for this research publication from any institution.

### Ethics Statements

The authors emphasized that no ethics committee permission was required for the preparation of the target compounds.

### Author Contribution

The two authors furnished the design, preparation of target compounds and interpretation of FTIR and <sup>1</sup>HNMR and antimicrobial activity of final compounds.

### References

1. Hadi MK, Rahim NA, Sulaiman AT, Ali RM. Synthesis, characterization and preliminary antimicrobial evaluation of new schiff bases and aminothiadiazoole derivatives of N-substituted phthalimide. *Research Journal of Pharmacy and Technology*. 2022; 15(9):3861-5.
2. Kamms ZD, Hadi MK. Synthesis, Characterization and preliminary Anti-Microbial Evaluation of New Ibuprofen Hydrazide Derivatives. *Pakistan Journal of Medical & Health Sciences*. 2022; 16(03):693-696.
3. Ahmed Mohsen, Alyaa Gomaa, Fatma Mohamed, Roaa Ragab, mennatallah Eid, Al-Hussein Ahmed, Areej Khalaf, Mohamed Kamal, Safaa Mokhta, Hadeer Mohamed, Islam Salah, Rania Abbas, Sameh Ali, Rehab Mahmoud Abd El-Baky, Antibacterial, Anti-biofilm Activity of Some Non-steroidal Anti-Inflammatory Drugs and N-acetyl Cysteine against Some Biofilm Producing Uropathogens, *American Journal of Epidemiology and Infectious Disease*, 2015; 3(1):1-9.
4. Naser AW, Al-Musawi AJ, Fadhil AA, Al-Shawi NN. Synthesis, characterization and anti-inflammatory evaluation of some new 2-(3-fluorobiphenyl-4-yl) propanoic acid derivatives. *International Journal of Pharmaceutical Sciences and Research*. 2017; 8(4):1598-05.
5. Alam A, Ali M, Rehman NU, Ullah S, Halim SA, Latif A, Zainab, Khan A, Ullah O, Ahmad S, Al-Harrasi A. Bio-oriented synthesis of novel (S)-flurbiprofen clubbed hydrazone schiff's bases for diabetic management: In vitro and in silico studies. *Pharmaceuticals*. 2022;15(6):672.
6. Khan M, Alam A, Khan KM, Salar U, Chigurupati S, Wadood A, Ali F, Mohammad JI, Riaz M, Perveen S. Flurbiprofen derivatives as novel  $\alpha$ -amylase inhibitors: Biology-oriented drug synthesis (BIODS), in vitro, and in silico evaluation. *Bioorganic chemistry*. 2018; 81:157-67.
7. Aydin S, Kaushik-Basu N, Arora P, Amartya BA, Nichols D, T TALELE T, Akkurt M, Çelik İ, Büyükgüngör O, Küçükgülzel ŞG. Microwave assisted synthesis of some novel Flurbiprofen hydrazidehydrazones as anti-HCV NS5B and anticancer agents. *Marmara Pharmaceutical Journal*. 2013; 17(1):26-34.
8. Bondi ML, Craparo EF, Picone P, Giammona G, Di Gesù R, Di Carlo M. Lipid nanocarriers containing ester prodrugs of flurbiprofen preparation, physical-chemical characterization and biological studies. *Journal of Biomedical Nanotechnology*. 2013; 9(2):238-46.
9. Abbas S, Zaib S, Ur Rahman S, Ali S, Hameed S, Tahir MN, Munawar KS, Shaheen F, Abbas SM, Iqbal J. Carbonic Anhydrase Inhibitory Potential of 1, 2, 4-triazole-3-thione Derivatives of Flurbiprofen, Ibuprofen and 4-tert-butylbenzoic Hydrazide: Design, Synthesis, Characterization, Biochemical Evaluation, Molecular Docking and Dynamic Simulation Studies. *Medicinal Chemistry*. 2019; 15(3):298-310.
10. Amir M, Kumar S. Synthesis of some new 2-(2-fluoro-4-biphenyl) propionic acid derivatives as potential anti-inflammatory agents. *Die Pharmazie-An International Journal of Pharmaceutical Sciences*. 2005; 60(3):175-80.
11. Hadi MK, Abdulkadir MQ, Abdul-Wahab AH. Synthesis and Antimicrobial Evaluation of Sulfonylhydrazide Derivatives of Etodolac. *International Journal of Drug Delivery Technology*. 2021;11(3):1000-1003.
12. Çıkla P, Tatar E, Küçükgülzel İ, Şahin F, Yurdakul D, Basu A, Krishnan R, Nichols DB, Kaushik-Basu N, Küçükgülzel ŞG. Synthesis and characterization of flurbiprofen hydrazide derivatives as potential anti-HCV, anticancer and antimicrobial agents. *Medicinal Chemistry Research*. 2013; 22:5685-99.
13. de Oliveira Carneiro Brum J, França TC, LaPlante SR, Villar JD. Synthesis and biological activity of hydrazones and derivatives: A review.

- Mini reviews in medicinal chemistry. 2020; 20(5):342-68.
14. Ali MR, Marella A, Alam MT, Naz R, Akhter M, Shaquiquzzaman M, Saha R, Tanwar O, Alam MM, Hooda J. Review of biological activities of hydrazones. *Indonesian Journal of Pharmacy*. 2012; 23(4):193-202.
  15. Popiołek Ł. Hydrazide–hydrazones as potential antimicrobial agents: overview of the literature since 2010. *Medicinal Chemistry Research*. 2017; 26:287-301.
  16. Rahmani SE, Lahrech M. Evaluation of the Antioxidant Activity of some Hydrazone Schiff's bases bearing Benzotriazole Moiety. *Research Journal of Pharmacy and Technology*. 2018; 11(9):4104-7.
  17. Sahib HA, Hadi MK, Abdulkadir MQ. Synthesis, and Antimicrobial Evaluation of New hydrazone Derivatives of (2, 4-dinitrophenyl) hydrazine. *Research Journal of Pharmacy and Technology*. 2022; 15(4):1743-8.
  18. Abdulhamza HM, Farhan MS. Synthesis, Characterization and Preliminary Anti-inflammatory Evaluation of New Fenoprofen Hydrazone Derivatives. *Iraqi Journal of Pharmaceutical*. 2020; 29(2):239-44.
  19. Hasan, Md Rakhilul, et al. In silico analysis of ciprofloxacin analogs as inhibitors of DNA gyrase of *Staphylococcus aureus*. *Informatics in Medicine Unlocked*, 2021, 26: 100748.
  20. Jwaid, MAZEN MOHAMMED, KARIMA FADHIL Ali, and MAYADA HADI Abd-Alwahab. "Design, synthesis, molecular docking and antibacterial evaluation of novel isoniazid derivatives bearing 1, 3, 4-oxadiazole and 1, 2, 3-triazol moieties Jwaid." *International Journal of Pharmaceutical Research* 12.4 (2020): 2277-2286.
  21. Saeed, Ali Mohammed, and Ayad Abed Ali Al-Hamashi. "Molecular Docking, ADMET Study, Synthesis, Characterization and Preliminary Antiproliferative Activity of Potential Histone Deacetylase Inhibitors with Isoxazole as New Zinc Binding Group." *Iraqi Journal of Pharmaceutical Sciences* (P-ISSN 1683-3597 E-ISSN 2521-3512) 32.Suppl. (2023): 188-203.
  22. Mohammed, Hamada HH, et al. Synthesis and molecular docking of new N 4-piperazinyl ciprofloxacin hybrids as antimicrobial DNA gyrase inhibitors. *Molecular Diversity*, 2023, 27.4: 1751-1765.
  23. Abbas S, Zaib S, Ali S, Iqbal J. 15-LOX Inhibitors: Biochemical Evaluation of Flurbiprofen and its Derivatives. *Life and Science*. 2020; 1(3):6-.
  24. Kamms ZD, Hadi MK. Synthesis, Characterization and Preliminary Antimicrobial and Anti-inflammatory Evaluation of New Ibuprofen Hydrazide Derivatives. *International Journal of Drug Delivery Technology*. 2023; 13(1):376-38.
  25. McMurry J. Ch. 21: Carboxylic acid derivatives: Nucleophilic acyl substitution, In: *Organic Chemistry*, 7th edition, Brooksby Thomson Learning, Inc., USA, 2008; P 785–841.
  26. Hmood KS, Ammar AR, Al-Bayati RI, Saleh AM. Synthesis, and anti-tumor evaluation of some new Flurbiprofen derivatives against MCF-7 and WRL-68 cell lines. *Indonesian Journal of Pharmacy*. 2021; 32(1):17-34.
  27. Abdulaheem SS, Hadi MK. Synthesis and Characterization of New Coumarin Derivatives as Possible Antimicrobial Agents. *International Journal of Drug Delivery Technology*. 2021; 11(4):1484-1490.
  28. Ibrahim MF, Abdel-Reheem HA, Khattab SN, Hamed EA. Nucleophilic substitution reactions of 2, 4-Dinitrobenzene derivatives with hydrazine: Leaving group and solvent effects. *International Journal of Chemistry*. 2013 Aug 1;5(3):33.
  29. Jabber MM, Hadi MK. Synthesis, Characterization, and Antimicrobial Evaluation of new Ibuprofen Derivatives. *Pakistan Journal of Medical & Health Sciences*. 2022; 16(03):689-.
  30. Abduljabbar TT, Hadi MK. Synthesis, Characterization and Antibacterial Evaluation of Some Coumarin Derivatives. *Iraqi Journal of Pharmaceutical Sciences*, 2021, 30(1):249-257.
  31. Carey FA, Sundberg RJ. Addition, condensation and substitution reactions of carbonyl compounds. In *Advanced Organic Chemistry* 2007 (pp. 629-711). Springer, Boston, MA.
  32. Farhan MS, Saour KY. Synthesis of some Novel Nitrogenous Heterocyclic Compounds with Expected Biological Activity as Antimicrobial and Cytotoxic Agents. *Iraqi Journal of Pharmaceutical Sciences* (P-ISSN 1683-3597 E-ISSN 2521-3512). 2015; 24(1):49-58.
  33. QikProp, Schrödinger, LLC, New York, NY (2021).
  34. Hassan, Omeed M., and Susan W. Sarsam. "Synthesis, characterization and preliminary anti-inflammatory evaluation of new etodolac derivatives." *Iraqi Journal of Pharmaceutical Sciences* (P-ISSN 1683-3597 E-ISSN 2521-3512) .(2019): 106-112.
  35. Cikli P, Ozcavci D, Sener A and Turan S. Synthesis, cytotoxicity and pro-apoptosis activity of Etodolac hydrazide derivatives as anti-cancer agents. *Arch Pharm*. 2013; 367(5), 367-379.

## تصنيع وتشخيص و تقييم أولي للمضادات الميكروبات لمشتقات فلوربيروفين هيدرازيد الجديدة

حوراء يسر جاسم<sup>1\*</sup> و محمد كامل هادي<sup>2</sup><sup>1</sup>وزارة الصحة، قسم الصحة في بغداد الرصافة، بغداد، العراق  
<sup>2</sup>آفرع الكيمياء الصيدلانية، كلية الصيدلة، جامعة بغداد، بغداد، العراق

## الخلاصة

تم تحضير سلسلة جديدة من مشتقات فلوربيروفين لزيادة فعاليتها المضادة للميكروبات. تم تحضير مركبات فلوربيروفين هيدرازون الجديدة (4a-e) من تفاعل إستر إيثيل فلوربيروفين مع هيدرازين هيدرات لتحضير فلوربيروفين هيدرازيد (3). ثم تم مفاعلة مركب (3) مع الدهيدات عطرية مختلفة في وجود حمض الخليك الثلجي. تم استخدام الأشعة تحت الحمراء و طيف الرنين المغناطيسي النووي لتحديد هياكل المركبات النهائية. أظهر برنامج التصميم الدوائي أن هناك ارتباط قوي مع البروتين المستهدف للمركبين (4d) و (4a) عند مقارنتهما بالدواء سيبروفلوكساسين كمرجع. أجريت دراسة تنبؤية للحركية الدوائية و السمية لجميع المركبات النهائية. تتميز المركبات النهائية بخصائص تقديرية مقبولة شبيهة للأدوية وخصائص دوائية مرغوبة. تم فحص جميع المركبات النهائية لفعاليتها المضادة للميكروبات ضد البكتيريا الموجبة لصبغة الغرام (البكتيريا العقدية المفحجة، البكتيريا الكروية العنقودية) و البكتيريا السالبة لصبغة الغرام (الكليسيلا الرنوي و الإشرىكية القولونية) و سلالة الفطريات (المبيضات البيضاء). أظهر المركب (4e) أعلى نشاط مضاد للميكروبات ضد كلا السلالتين السالب و الموجب لصبغة الغرام من البكتيريا. بالإضافة إلى ذلك، يُظهر المركب (4b) فعالية جيدة لكلا السلالتين. تظهر جميع المركبات المصنعة باستثناء المركب (4b) فعالية عالية مضادة للفطريات المبيضات البيضاء عند مقارنتها بالمركب القياسي، فلوكونازول.

الكلمات المفتاحية: فلوربيروفين، هيدرات الهيدرازين، الفعالية المضادة للميكروبات، مضادات الالتهاب غير الستيرويدية